Across the continent , ACE-031, in its 1mg strength, is gaining traction as a promising therapy for a targeted disease area. Current studies in countries like the Federal Republic and France are investigating its impact on clinical results . Agencies throughout Europe are keeping a watch on the development of ACE-031, with future clearance expected